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Nmuc oxide has enigmatic qualities in inflamma-
tion. In order to appreciate the precise contribu-
tions of nitric oxide to a pathophysiological
process, one must account for enzyme source, co-
production of oxidants and antioxidant defences,
time, rate of nitric oxide production, cellular
source, peroxynitrite formation and effects on
DNA (mutagenesis/apoptosis). We contend that
there is ample evidence to consider nitric oxide
as a molecular aggressor in inflammation, parti-
cularly chronic inflammation. Therapeutic
benefit can be achieved by inhibition of inducible
nitric oxide synthase and not the donation of
additional nitric oxide. Furthermore, there is
growing appreciation that nitric oxide and
products derived thereof, are critical components
linking the increased incidence of cancer in
states of chronic inflammation.
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Solution chemistry of nitric oxide
Organic chemists have known for some time that
cigarette smoke and atmospheric pollutants gen-
erated from the combustion of petroleum-based
and other organic products (automobile exhaust,
industrial smoke) contain high concentrations of
a variety of oxidized metabolites of nitrogen
(Table 1). Many of these same nitrogen oxides,
collectively called NOx and which are ultimately
derived from NO, are produced by mammalian
cells.
NO is a colourless gas that contains an odd
number of electrons and is, by definition, a free
radical. The unpaired electron is delocalized over
the nitrogen and oxygen atoms. NO is relatively
unstable in the presence of molecular oxygen
with an apparent half-life of approximately 3-
5 s. It will rapidly decompose in the presence of
O2 to yield a variety of nitrogen oxides in a
12 complex series of interactions:’
2NO + 02 2NO2
2NO + 2NO2 > 2N203
2N203 + 2H20 > 4NO2- + 4H +
where NO2, N203 and NO2- represent nitrogen
dioxide, dinitrogen trioxide and nitrite, respec-
tively.
Although this reaction pathway has been pro-
posed to occur in aqueous (i.e. physiological)
solutions, there is some controversy as to
whether N203 is formed as an intermediate.’4
There is no doubt that the only stable product
formed by the spontaneous auto-oxidation of
(C) 1995 Rapid Science Publishers
NO in oxygenated solutions is NO2-,
2 However,
when urine or plasma are analysed, pre-
dominantly NO- is found in these extracellular
fluids. Although the mechanisms by which NO is
converted to NO- in vivo are not entirely clear,
there are at least two possibilities. Ignarro et al.
2
have suggested one mechanism in which the
NO2- derived from NO autooxidation is rapidly
converted to NO- via its oxidation by certain
oxyhaemoproteins (P-Fe
2+O2) such as oxyhae
moglobin or oxymyoglobin:
2P-Fe2+O2 + 3NO2- + 3NO2- + 2H+
> 2P-Fe3+ + 3NO3- + H20
or
4P-Fe2+O2 + 4NO2- + 4H+ + 4H+
: 4P-Fe3+ + 4NO3-+ 02 + 2H20
It should be noted, however, that these investi-
gators used large concentrations of NO (300 t.tM)
which will rapidly auto-oxidize to NO2-. Although
the authors suggested that the NO2-would in
Table 1. Oxidized metabolites of nitrogen
Symbol Name Comments
NO" Nitric oxide Free radical
NO2" Nitrogen dioxide Free radical; oxidizing agent
N20 Nitrous oxide Anaesthetic
N203 Dinitrogen trioxide Nitrosating agent
N204 Dinitrogen tetroxide Dimetric NO2; nitrosating
agent
NO2- Nitrite Produces nitrosating agent at
acidic pH
NO3- Nitrate Stable anion
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Table 2. Factors influencing the role of nitric oxide in
inflammation
1. Oxidant levels and metal-binding sites
2. Enzyme source (cNOS only vs. iNOS)
3. Time (iNOS expression, repair vs. injury)
4. Concentration (products of second-order kinetics: N203, N204)
5. Cellular source
6. Interactions with other oxidants/substrates (ONOO-)
7. Gene expression/DNA damage (mutagenesis, apoptosis)
turn react with the haemoproteins, this reaction
is quite slow, requiring 2-3 h.
2 A second, possi-
bly more reasonable explanation for the pre-
sence of predominantly NO- in vivo may have
to do with the fact that the levels of NO pro-
duced by nitric oxide synthase (NOS) in vivo
would be much smaller and thus the half-life of
NO would be much longer. In this case, NO
would react directly and very rapidly with oxy-
haemoproteins to yield NO- before it has an
opportunity to auto-oxidize to NO2-.
5
Thus, it is within this background that the
complexity of NO chemistry can be appreciated.
A family of oxidative products is generated under
physiological conditions. These oxidative pro-
ducts may have similar or contrasting effects to
the parent nitric oxide or alternatively no biologi-
cal consequence (Table 2).
Mechanisms of NO-dependent tissue
injury and dysfunction
Metabolic inhibition: Several groups of investiga-
tors have demonstrated that the large amounts of
NO produced from activated macrophages are
capable of injuring hepatocytes, pancreatic islet
cells, and lymphocytes. The mechanisms by
which NO injures cells appears to include intra-
cellular iron release, inhibition of mitochondrial
function and inhibition of DNA synthesis. It is
known for example, that NO will inhibit three
mitochondrial enzymes including acotinase (tri-
carboxylic acid cycle), NADPH-ubiquinone oxi-
doreductase and succinate-ubiquinone
oxidoreductase (Complex I and Complex II or
the mitochondrial respiratory chain).-s This
inhibition is a result of the NO-mediated degra-
dation of the iron-sulfur clusters associated with
these three enzymes. This interaction most prob-
ably accounts for the NO-mediated release of
nonhaem iron from certain target cells.9 In addi-
tion, NO has been shown to inactivate ribonu-
cleotide reductase, which may account for its
ability to inhibit DNA synthesis.
Influence of time: There is a wealth of literature
indicating either that NO donors protect or NOS
inhibitors exacerbate tissue injury to an acute
insult. Virtually all these studies have all been
acute in nature, i.e. experimental protocols were
only a few hours in duration. One may pose the
question, "How can time influence the role of
NO in a state of inflammation?" The answer lies
primarily in expression of iNOS. Nitric oxide
promotes tissue injury when it is produced in
excess, but the isoform which produces large
quantities of NO (iNOS) is regulated at the tran-
scriptional level. In other words, to proceed from
stimulus and activation of iNOS expression via
transcription of the gene and its translation into
new iNOS protein and the formation of excess
NO, takes a defined period of time. Under ideal
circumstances this process takes several hours
but in a disease where the stimuli may vary in
amount and relative importance, then the expres-
sion of iNOS may be delayed even further. Until
this point is reached only limited production of
NO can be achieved.
An excellent example of this phenomenon has
come from the laboratory of Drs Brendan
Whittle and Salvador Moncada. In 1990 they
reported that the NO donor S-nitroso-N-acetyl-
penicillamine attenuated endotoxin-induced acute
intestinal damage,
1 suggesting that NO was pro-
tective over the 3 h of the experimental protocol.
In a follow-up study reported 4 years later,
1 they
confirmed the initial report; the NOS inhibitors
t-NAME or t-NMMA, exacerbated endotoxin-
induced vascular injury when administered at the
same time as endotoxin and evaluated 2h later.
If, however, administration of the NOS inhibitors
was delayed until 3 h after endotoxin administra-
tion and the protocol extended for an additional
2h (total of 5h) then the NOS inhibitors were
protective. Thus, in the matter of hours NO had
transformed from an agent which was anti-
inflammatory to one which was now pro-inflam-
matory. Although not confirmed by this group,
the likely reason for this transformation is the
time required for the expression of iNOS. Endo-
toxin is a classic stimulant for the expression of
iNOS and expression of iNOS has been noted
after ischaemia/reperfusion injury.
12
Few studies have addressed the effects of NO
donors on a chronic inflammatory process,
although there is ample evidence of NOS inhibi-
tors being therapeutic in chronic inflamma-
13 16 tion. Our colleagues in this debate have
shown in models of gastric ulceration that
NSAIDs that contain a NO-donating moiety are
protective when compared to the parent com-
17 18 pound without the NO donor structure. The
mechanisms for this phenomenon are not clear.
While a vascular effect and a role of cGMP-based
mechanisms has been proposed, an effect on
microbial flora remains a possibility. Nitric oxide
is a mediator of host defence and any limitation










Complexes reactive nitrogen species oxygen species





--"[---- N 5 ONOO"
4 Peroxynitrite
Fe,Cu,Co,Mn N +a




metals NO sequestrants e .e z *
eom mutanon / ONOOH (pH7) Disrupts catalytic
sites Disrupt disulfide .,,rosam,nes
Bridges
Prevents’OH formation I
FIG. 1. Sites of action and interaction by nitric oxide in inflammation.
on bacterial translocation at the site of the ulcer been highlighted .by the application of stroke
may potentially promote healing, models to nNOS knock-out mice.
22 In animals
Are there conditions where cNOS acts like lacking nNOS the administration of an NOS inhi-
iNOS; and if so, under these conditions should bitor resulted in an exacerbation of the injury,
NOS inhibition be protective even if the proto- when studied acutely. Furthermore, there is evi-
cols were acute? The answers to these questions dence that the redox state of NO may account
are yes and yes! Stroke is an acute condition for23 neuroprotective or neurodestructive roles.
associated with an immediate and sustained If nNOS acts like iNOS in acute stroke is there
release of NO, and neuronal injury can be ame- a role for iNOS itself in stroke? It appears that if
liorated by attenuating the activity of the neuro- the protocol length is extended an iNOS-only
nal isoform of cNOS (nNOS). Neuronal NOS, like contribution to the overall condition
4 can be
the endothelial constitutive isoform, eNOS, is seen. Inducible NOS can be expressed in
regulated by the intracellular levels of calcium neurons and glia.
25-27 In this respect there is an
and activation of calmodulin. In contrast, the inflammatory component to cell death in stroke,
inducible isoform, iNOS, has calcium-activated this component involves iNOS and is apparent
calmodulin as an integral subunit, and therefore hours to days after the initiation of neuronal
iNOS activity is independent of intracellular injury. Administration of aminoguanidine, an NOS
calcium fluxes.19 In stroke NMDA receptor activa- inhibitor with selectivity for iNOS, was beneficial
tion maintains intracellular calcium at a high in experimental stroke when administered 6h
level. Consequently nNOS activation is sustained, after the initiation of stroke.
28
as opposed to the normal pulsitile manner, and
as a result, large, sustained release of NO results Influence of enzyme source---iNOS vs. cNOS:
in exacerbation of the initial neuronal injury. With the exception of acute neuronal injury asso-
There are reports that NOS inhibitors are not ciated with stroke, a reasonable generalization is
20 21 neuroprotective. This can be reconciled as that one can predict the role nitric oxide will
the result of impairing endothelial NOS activity play in a disease process by determining the pre-
and exacerbating the vascular complications and sence or absence of iNOS. If iNOS is absent then
granulocyte infiltration response associated with NO will primarily exhibit anti-inflammatory
stroke. These contrasting roles of the neuronal effects. Conversely, the presence of iNOS is an
and endothelial NOS isoforms in stroke have excellent indicator that NO is directly contribut-
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ing to tissue injury. This generalization is blurred by pharmacological probes which were not
in states of infection where NO generated from selective for iNOS (either L-NAME or t-NMMA) in
iNOS is necessary for killing the invading micro- TNBS ileitis3 streptococcal cell wall arthritis or
organisms and inhibition of NO formation may colitis4’5 or adjuvant arthritis,2’’5 or sponta-
promote the growth and extent of infiltration of neous glomerulonephritis in mice.36 With the
this infection and enhance the resultant tissue availability of inhibitors with greater selectivity for
injury. Nevertheless, there is evidence that in inducible NOS, e.g. aminoguanidine or -NIL (N-
experimental pneumococcal meningitis excess iminoethyl-lAysine) therapeutic benefit has also
NO formation contributes to the brain oedema been observed in a range of chronic inflamma-
and meningeal inflammation.29 For the purposes tory states, e.g. peptidoglycan-polysaccharide
of this debate we will exclude the complications induced chronic granulomatous colitis,
5 adjuvant
of infection, focusing rather on autoimmune dis- arthritis,
6 TNBS and adjuvant ileitis26’ and auto-
eases or non-infectious inflammation, immune encephalomyelitis in SJL mice.37
There are relatively few studies which have We have also described a mild ileitis induce6
directly assessed iNOS gene expression in disease by chronic administration of the NOS inhibitor,
states, particularly over the time-course of the L-NAME, in otherwise normal guinea-pigs.8’39
inflammatory condition. In models of gut inflam- While superficially this is consistent with a loss of
mation we have observed iNOS gene expression the physiological anti-inflammatory actions of
at the onset of symptoms in the TNBS (trini- nitric oxide, when we further addressed indices
trobenzene sulfonic acid) model of ileitis and of nitric oxide formation there was no evidence
colitis3 and adjuvant ileitis. In the TNBS model of attenuated NO formation. Rather, all indices
iNOS gene expression is apparent 1 day after the suggested that nitric oxide formation was
administration of TNBS and maintained for the increased in conjunction with increased levels of
first week of inflammation, as determined by RT- cGMP. In order to explain this perplexing phe-
PCR and Western blotting. In contrast, in the nomenon we addressed iNOS gene expression
adjuvant model of ileitis, in an analogous manner and noted that chronic administration of t-NAME
to adjuvant arthritis, the onset of symptoms is results in the expression of iNOS. This response
delayed until about 10 days after administration of was not isolated to the gut, being apparent in
the adjuvant. In keeping with the role of iNOS in lung, vasculature and uterus, in rats and guinea-
the initiation of inflammation, the expression of pigs. It appears that chronic reductions in NO
iNOS is apparent in this model at day 14 but not release can result in the expression of iNOS in
at day 7. Similarly, increased production in HLA- order to compensate for inadequate levels of
B27 transgenic rats is only noted at the onset of NO. This effective mechanism for restoring NO
symptoms and persists for the duration of the production is not without complications as iNOS,
spontaneous colitis that they exhibit.3 once formed, is poorly regulated and can result
The expression of iNOS has also been repor- in excess NO formation which may account for
ted in models of arthritis initiated by adjuvant
6 the leukocytosis, ileitis and increased endothelin
and streptococcal cell wall fragments.
4 The levels associated with chronic L-NAME administra-
expression of iNOS coincides with increased tion.38’4 This phenomenon is probably only
production of nitric oxide and the initiation of achievable because t-NAME is slightly selective
inflammatory symptoms. While the loss of matrix for cNOS; iNOS selective inhibitors do not
proteoglycans from articular cartilage is a hall- display this response. Thus it is important to
mark of destructive joint disease like osteoar- veriB7 if the administration of an NOS inhibitor
thritis or rheumatoid arthritis and may well has reduced NO formation, particularly if admi-
involve NO-related mechanisms, it is now appre- nistered chronically, otherwise the data may be
ciated that nitric oxide can inhibit glycosami- interpreted incorrectly.
noglycan synthesis.32-34 In other words natural If NO is primarily anti-inflammatory, states of
repair mechanisms may also be compromised by tissue injury and inflammation should be char-
nitric oxide. While this is compelling circum- acterized by a reduction in NO levels. This is not
stantial evidence suggesting that NO is involved the case; states of inflammation are virtually
in the disease process, these associations do not always characterized by increased NO levels. This
reveal the role of NO in that process. Never- is more consistent with the pro-inflammatory role
theless, with chronic administration of NOS inhi- of NO, otherwise the interpretation is that NO is
bitors it is readily demonstrated that the anti-inflammatory but its efficacy is quite weak.
expression of iNOS and increased synthesis of As many of the disease states demonstrating a
NO in inflammation is a major contributor to pro-inflammatory role of NO via expression of
tissue injury in these states of inflammation, iNOS are autoimmune in character, it is logical to
Initially, therapeutic benefit was demonstrated expect that organ transplant rejection responses
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may also involve iNOS. Recently Worrall et al. arthritis.
62 Biochemical or immunohistochemical
described that iNOS is expressed in allogenic evidence suggests that iNOS is expressed in these
cardiac transplants in rats during the rejection disease states and probably accounts for the
response, in association with increased systemic increased production of nitric oxide. We postu-
levels of nitrate/nitrite.
41 Further, administration late that the role of this exaggerated production
of the iNOS inhibitor, aminoguanidine, pro- of nitric oxide in these human diseases will par-
longed graft survival and significantly reduced allel animal models, i.e. nitric oxide will be pro-
histological indices of rejection, inflammatory.
Them is an expanding list of induced and
spontaneous disease states which are character- Cellular sources of iNOS in inflammation: Tradi-
ized by exaggerated release of nitric oxide and tionally, iNOS is associated with macrophages
inhibitors of NOS display therapeutic efficacy, and to a lesser extent granulocytes, because
These include HLA B27 transgenic rats with these are the cell types in which iNOS activity
spontaneous intestinal inflammation,
31 colonic was discovered. It is now apparent that many cell
inflammation induced by the sulfhydryl blocker, types can express iNOS but in contrast, the neu-
iodoacetamide,
42 insulin-dependent diabetes mel- ronal and endothelial forms of NOS remain loca-
litus,43 carrageenan-induced pleurisy and footpad lized in their original classification with the
44 45 46 oedema, endotoxin-induced uveitis, air exception of epithelial cells and skeletal muscle
47 pouch models of granuloma formation, TNBS which express cNOS.63 Thus, in an inflammatory
and acetic acid colitis in rats48’49 and sponta- disease state iNOS is expressed in a variety of
neous, idiopathic colitis in rhesus macaques.
5 cells and not just in infiltrating leukocytes. In
Nitric oxide displays anti-inflammatory char- arthritis, chondocytes, osteoblasts and synovium
acteristics in ischaemia-reperfusion injury.
51-53 can be a source of NO.16’32’64’65 In gut inflamma-
These protocols are acute and therefore are tion the lredominant sources of iNOS are epi-
iNOS-independent models, although with exten- thelia26’’6’6 and the enteric nervous
sion of the study period iNOS can be detected in system,26’3 in addition to resident and infiltrating
previously injured tissue.
2 Recently, a report has leukocytes in the lamina propria. Tepperman and
addressed the role of nitric oxide in ischaemia- colleagues first described the ability of endotoxin
mperfusion injury in a condition where iNOS is to increase NO synthesis in cultured epithelial
present, i.e. after administration of endotoxin. Ma cells, a response which led to epithelial cell
and colleagues noted that reperfusion injury was death via NO-dependent mechanisms.66’67 Fur-
attenuated by the NOS inhibitor t-NMMA under thermore, it appears that the epithelium
these conditions, as opposed to the usual responds to this NOx-induced stress and resul-
exacerbation seen in the absence of endotoxin.54 tant DNA damage by undergoing apoptosis.
68
They proposed, based on the evaluation of che- Epithelial barrier function, conferred by tight
miluminescence signals, that excess NO reacted junctions between epithelia, is influenced by
with superoxide induced by ischaemia-reperfu- nitric oxide. Inhibition of nitric oxide synthesis
sion, to form the highly toxic peroxynitrite, compromises epithelial barrier dysfunction under
which in turn contributed to hepatocellular basal conditions and in ischaemia reperfusion
injury. This is another example of NO promoting injury.52’53’69 Following an acute injury where the
tissue injury when conditions are favourable, viz. epithelial barrier becomes leaky there is a rapid
during states in which iNOS is expressed, repair/restitution response. This response is
In human disease there remains a lack of solid impaired by NOS inhibitors,
7 although a con-
evidence that inhibition of NOS is protective, trasting result in the Caco-2 cell line has been
largely because compounds with sufficient selec- reported.
7 Because of the importance of the
tivity for iNOS are not available for testing. The epithelial barrier in limiting the translocation on
exception is the preliminary work in septic shock luminal flora and contents any impairment of this
with -NMMA.55 In shock a complete withdrawal barrier would promote the inflammatory
of nitric oxide synthesis may be deleterious, response. In the acute (iNOS absent) models NO
leading to suggestions that scavengers that mop- promotes the integrity of this barrier and there-
up excess NO may be viable alternatives. One fore is anti-inflammatory. In chronic gut inflam-
interesting NO scavenger is hydroxocobalamin, a mation there is also epithelial barrier dysfunction
form of vitamin B12 lacking cyanide, which pre- concomitant with exaggerated nitric oxide
vents and reverses endotoxic shock in rats and release,1’2’ but in these states NOS inhibitors
mice.56 are protective.
Nevertheless, there is ample evidence of What could be the explanation for this appar-
excess nitric oxide formation in human diseases, ent discrepancy? We propose that these differ-
including ulcerative colitis,57-59 gastritis6’61 and ences are mediated by contrasting mechanisms.
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Under acute conditions the beneficial effects are
mediated by cGMP, indeed cGMP mimics
decreased epithelial permeability. In contrast, in
iNOS-dependent chronic inflammation the
increase in epithelial permeability is the result of
increased epithelial cell injury and/or death. It
does not matter how tight the tight junctions are
if there is rampant epithelial cell death, leukocyte
emigration and substantial morphological
derangementscrypt abscesses, ulceration and
bursting of villus tips. These morphological
derangements, characteristic of mucosal inflam-
mation, will promote epithelial barrier dysfunc-
tion.
Pathways of NO metabolism--is injury
due to NO or NOx?
Nitric oxide itself is a poorly reactive free radical,
and in order for it to be a major component of
cellular injury it is likely to be metabolized to
alternative species. In an analogous manner
superoxide (O2-) is a weakly reactive reactive
oxygen species but it is metabolized in inflam-
mation to a cascade of more reactive products,
e.g. HOCl and OH’. Nitric oxide is inactivated by
oxidation to nitrite (NO2-) and subsequently
nitrate (NO-) but other oxidized forms may be
formed which are not innocuous. Some products
require two molecules of nitric oxide as sub-
strate for the generation of the product, e.g.
N203 and N204. In other words, these reactions
display second-order kinetics and large amounts
of the substrate are required to drive the reac-
tion. Thus, it is likely that only in conditions in
which iNOS is expressed will these products be
formed. One of the consequences of these reac-
tive nitrogen species results from their ability to
act as nitrosating and nitrating species. If the
target is DNA then this will lead to deamination
and point mutations, as indicated in Table 3.
74,75
Interaction between Of and NO.. Recently bio-
chemical studies have demonstrated that 02 and
NO rapidly interact via a radical-radical reaction
at a diffusion-limited rate (k 6.7 x 109 m-l.s-1)
to generate the potent oxidant peroxynitrite
77 78 (ONOO-).76 Beckman and co-workers have
suggested that the interaction between these two
Table 3. Types of alterations and mutations that may arise from
the deamination of DNA bases
Conversion Type of mutation
Cytosine + NOx Uracil G:C A:T
mCytosine + NOx Thymine G:C . A:T
Guanine + NOx Xanthine G:C A:T
Adenine + NOx Hypoxanthine A:T G:C
free radicals to yield ONOO- and its conjugate
acid, peroxynitrous acid (ONOOH), enhances
dramatically the toxicity of either O2- or NO
alone. Indeed, it has been demonstrated in vitro
using pre-formed or chemically synthesized
ONOO-/ONOOH that these oxidants are capable
of directly oxidizing carbohydrates,v sulfhy-
dryls,78’79 lipids
8 and DNA bases,m as well as
mediating bactericidal and endothelial cell toxi-
city.77’82’83 It also has been demonstrated that the
stimultaneous production of NO and O2- by mac-
rophages may result in the formation of ONOO-/
ONOOH.
84
Although ONOO-is relatively stable, especially
at alkaline pH, it has a pK of 6.6 which dictates
that substantial amounts of this compound will
be protonated at physiological pH to yield per-
oxynitrous acid (ONOOH). This compound is
very unstable and has been suggested to rapidly
decompose to yield a hydroxyl radical (OH’)
and NOi-like compound.
ONOOH 2
o NO + OH’’
This hydroxyl radical-like oxidant will react
with virtually all biomolecules at diffusion limited
rates of reactions ( 10v-10 M-1. s-). Nitro-
gen dioxide is also a very reactive radical with an
ability to react with alkanes and alkenes via free
radical-mediated mechanisms.8’8 Furthermore,
Pryor and coworkers have demonstrated that
NO2= will initiate lipid peroxidation in vitra85’86
They also demonstrated that abstraction of H
atoms from unsaturated lipid by NO2" resulted in
the formation of nitrous acid HONO which was
shown to N-nitrosate certain amines to yield
nitrosamines.85’86 In addition, NO2" is known to
react with haemoproteins such as haemoglobin
and oxidize thiols and thioethers (methio-
nine).85’86 Taken together, these data suggest that
if the decomposition of ONOOH proceeds via
the formation of OH-like species and NO2" then
it represents a potentially important pathway in
which toxic oxygen and nitrogen-derived free
radicals may be formed from the interaction
between two relatively unreactive radicals, O2-
and NO. In fact, this mechanism has been pro-
posed to account for the 02- dependent micro-
vascular injury produced by ischaemia and
reperfusion of various organ systems.
Because of the ephemeral nature of peroxyni-
trite it is difficult to measure it in vitro, but it can
be tracked in situ by its ability to promote nitra-
tion reactions, in particular the formation of
nitrotyrosine. We have demonstrated that nitro-
tyrosine formation is negligible under basal con-
ditions but in inflammation it is readily
demonstrable by immunohistochemistry. Impor-
tantly, nitrotyrosine co-localizes with the expres-
392 Mediators of Inflammation Vol 4 1995NO and NOx and inflammation
sion of iNOS, and therapy with inhibitors of NOS but yet is accompanied by cellular/tissue growth
prevents the formation of nitrotyrosine (and pre- and immunosuppression. The explanation for
vents the inflammation). Thus, although nitric this dichotomy may lie in the production of
oxide itself cannot form nitrotyrosine (it would other oxidants. Unlike inflammatory conditions
form nitrosylate not nitrate tyrosine residues), the where nitrotyrosine and iNOS co-localize26’3
formation of NO from iNOS is linked to nitrotyr- nitrotyrosine is not present in the pregnant
osine formation, uterus or placenta. This suggests that interactions
Nitrotyrosine has been demonstrated in several between NO and other reactive oxygen species
human-disease states--atherosclerosis and amy- are critical determinants of the cytotoxic effects
trophic lateral sclerosis.87-89 Using HPLC techni- of nitric oxide. If pregnant rats are challenged
ques nitrotyrosine was readily detectable in joints with endotoxin, nitrotyrosine formation and cel-
of patients with rheumatoid or osteoarthritis9 lular injury can be demonstrated in the utero-
and absent in healthy individuals. Furthermore, placental unit (unpublished data, MJSM). As the
we have found that nitrotyrosine co-localizes with synthesis of oxygen free radicals is elevated by
iNOS and DNA fragmentation in Helicobacter endotoxin and inflammation in general, interac-
pylori gastritis and that eradication of the infec- tions with nitric oxide may be a critical determi-
tion or treatment with the antioxidants, ascorbic nant of the role reversal of nitric oxide.
acid and/or beta-carotene, reduces the staining
for nitrotyrosine.
1 Mutagenesis, DNA damage and
Studies from Radi’s laboratory have clearly apoptosis
demonstrated some of the potential toxic effects As previously mentioned, NO will spontaneously
of peroxynitrite, including inhibition of cell auto-oxidize to yield potent N-nitrosating agents
proliferation, DNA synthesis, succinate de- such as N203. This nitrosating agent may then
hydrogenase, fumarate reductase, thereby interact with secondary amines to yield poten-
suppressing mitochondrial electron transport tially carcinogenic nitrosamines. It is known that
chain in the parasite Trypanosoma.91’92 In addi- nitrosamines must be activated into mutagenic
tion, inhibition of alpha-proteinase inhibitor has and carcinogenic species via the action of the
been reported.9 Direct luminal administration of cytochrome P450 system. In addition, it has been
peroxynitrite can cause colitis in rats.94 demonstrated that electrophilic or mutagenic
While it is unlikely that all the deleterious metabolites may be generated from nitrosamines
effects of nitric oxide are due to peroxynitrite, via a cytochrome P-450 independent pathway
the kinetics for the formation of peroxynitrite involving the interaction of nitrosamines with
exceed that for dismutation of superoxide by highly reactive oxy radicals, such as OH’, or with
superoxide dismutase.77’78 In other words, co- ultraviolet light. Both the P450-dependent and
production of superoxide and nitric oxide will independent pathways appear to involve the for-
lead to the formation of peroxynitrite unless the mation of the a-hydroxynitrosamine intermediate.
NO is sequestered or oxidized. Thus the dis- This unstable intermediate, will spontaneously
crepancies which outline the current debate, i.e. decompose to yield the monoalkylnitrosamine
is nitric oxide inherantly anti- or proinflammatory derivative. Through a series of spontaneous re-
may be moot because the benefit/injury may be arrangement and decomposition reactions this
mediated by entirely different chemical species, intermediate will produce the alkylcarbonium
Low doses of nitric oxide are anti-inflammatory cation which is the ultimate carcinogen. This
whereas high concentrations of NO in conjunc- electrophilic agent will rapidly alkylate a variety of
tion with the release of other reactive oxygen different nucleophilic sites in cellular compo-
species, will lead to the formation of NO-derived nents including protein, DNA and RNA. It has
reactive nitrogen species that are pro-inflamma- been determined that alkylation of DNA may
tory. occur at as many as twelve different sites includ-
Further evidence that this maybe an important ing the ring nitrogen positions in adenine,
explanation is found in pregnancy. Our postulate guanine, cytosine and thymine, the oxygen atoms
is that nitric oxide production only has pro- associated with the hydroxyl or carbonyl groups
inflammatory effects when it is produced in of guanine, thymine and cytosine, and the phos-
excess, i.e. when iNOS is expressed. If this pos- phate groups. Experimental data suggests that
tulate is valid then exceptions should not be Cfi-alkylation of guanine represents one of the
observed. In other words, are there conditions in most important reactions because there is a
which iNOS is expressed but not associated with better correlation of the extent of O6-alkylation
tissue injury? Pregnancy is the exception. Preg- with carcinogenicity and mutagenicity than with
nancy is a state in which iNOS is expressed in a any other type of alkylation reaction. Alkylation
sustained manner in the uterus and placenta95 of guanine for example would alter the base
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pairing such that during DNA replication thymine
and not cytosine may be incorporated into the
newly synthesized strand of the nucleic acid.
Mutational effects of this type may then activate
certain oncogenes, resulting in malignant trans-
formation.
More recent studies have demonstrated that
NO may promote mutagenesis via nitrosative dea-
mination of DNA.96’97 It has been known for
many years that NO-derived nitrosating agents
(e.g. N203) will nitrosatively deaminate a variety
of primary aromatic amines (AR-NH2) to yield
their hydroxy derivatives. The mechanism
appears to involve the N-nitrosation of AR-NH2 to
yield a nitrosamine (Ar-NH-NO) intermediate.
This unstable intermediate will rapidl+y rearrange
to produce the diazonium ion (ar-N2) which in
turn decomposes to yield the hydroxyl derivative
(Ar-OH) of the aromatic amine:
ar-NH2 --
NOx > AR-NH-NO
ArN + AR OH 2
From these reactions it has been suggested that
deamination of cytosine (C), methyl cytosine
(mC), guanine (G) or adenine (A) would result in
the formation of uracil (U), thymine (T), xanthine
(X), and hypoxanthine (HX), respectively.
97 If
these types of reactions occur in intact DNA then
base pair substitution mutations may occur. There
are two major types of base pair substitution
mutations: one type involves the substitution of a
purine for purine or a pyrimidine for a pyrimidine
and is termed a transition mutation. The other
type is called a transversion mutation and is char-
acterized by the substitution of pyrimidine for a
purine or vice versa.
Deamination of cytosine to yield uracil for
example, will result in the removal of uracil by
the enzyme uracil glycosylase leaving an abasic
site. This type of lesion is commonly misrepaired
by insertion of adenine opposite the site during
replication resulting in the observed G:C to A:T
base pair substitution mutation (Table 3).97 If
uracil is not repaired it will pair with an incom-
ing adenine to give the same mutation upon
replication. Deamination of methyl cytosine to
yield thymidine would also produce a G:C to A:T
transition (Table 3). This type of mutation is
especially significant in mammalian cells because
the pattern of methylation of DNA is very impor-
tant in regulating gene expression and differ-
entiation. In addition to the misrepair of
deaminated bases, the instability of hypoxanthine
and xanthine in DNA formed from the deamina-
tion of adenine and guanine, respectively, leads
to rapid depurination forming apurinic sites. It is
thought that depurination leads to DNA breakage
and subsequent cytotoxicity as well as mutageni-
city. Base pair substitution mutations arising from
the nitrosative deamination of adenine and
guanine would lead to A:T to G:C and G:C to T:A
transversion mutations, respectively (Table 3).97
Based upon the relative rates of NO-dependent
deamination of the different bases in DNA, one
would expect the G:C to A:T transition mutations
to predominate. Indeed, this type of mutation
has been shown to predominate in mutants
(revertants) of Salmonella yphimurium pro-
duced by exposure of these cells to NO.96
Nitric oxide has been shown to promote
apoptosis in cancer cell lines, macrophages and
colonic epithelial cells.68’98’99 The mechanisms by
which NO may initiate cell death (apoptosis or
necrosis) vs uncontrolled cell replication
(cancer) may not be as divergent as they super-
ficially appear. Both involve DNA damage. A
normal cell whose DNA is damaged by NO, oxi-
dants or the combination, will arrest its cell cycle,
undergo DNA repair, or alternatively undergo
apoptosis, if the damage is perceived as too
extensive. Both the repair and apoptosis pro-
cesses protect the host from the duplication of
damaged DNA, with injured cells repaired or
eliminated. Survival of transformed cells may
occur if either the repair of apoptosis mechan-
isms are not effectively evoked. It is commonly
considered that cancer results in failures of mul-
tiple fail-safes (mmour suppressor and proto-
oncogene) and NO may play a role at all levels.
In those ’acute’ protocols where no deleterious
effects are noted, and where high doses of nitric
oxide are administered, or in conditions favour-
able for peroxynitrite formation, an evaluation of
DNA status is invariably absent. Unless mutagen-
esis or induction of apoptosis has been ruled
out, there is no assurance that serious complica-
tions have not been set into motion. Complica-
tions that may remain cloaked to standard
physiology-based tests and functional assays.
Concluding remarks
There is ample evidence that nitric oxide is a
molecular aggressor in inflammation. The repor-
ted anti-inflammatory actions are either very
acute in duration and/or pertain to conditions
which are not classically defined as inflammation,
but rather states which are primarily driven by
oxygen free radicals, e.g. ischaemia/reperfusion
injury. Furthermore, NO formation is greatly ele-
vated in inflammation suggesting that if its
primary role was anti-inflammatory its actions are
too weak to negate tissue damage. Rather, it
appears that NO is primarily pro-inflammatory in
inflammatory disease states. For this reason new
therapeutic approaches for the treatment of
chronic inflammatory diseases such as arthritis
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and inflammatory bowel disease, focus on the
inhibition of inducible nitric oxide synthase, and
not the use of NO donors.
In the last few years we have come to appreci-
ate that the pro-inflammatory actions of nitric
oxide involve a multitude of mechanisms. It is
likely that the critical events may involve reactive
nitrogen species derived from nitric oxide, but
the parent radical is not, in itself, the mediator of
tissue destruction. Peroxynitrite, at this time,
appears to be the best candidate but other reac-
tive nitrogen species may assume the mantle cur-
rently bestowed on peroxynitrite. Further, nitric
oxide and related products appear to be chemi-
cal links between inflammation and cancer by
virtue of their ability to react with DNA bases,
causing point mutations.
In summary, nitric oxide is clearly a critical
pro-inflammatory mediator. The dilemma estab-
lished by its anti-inflammatory actions under
basal conditions can be reconciled by evaluating
the influence of time on the observations, the
enzyme source of nitric oxide production, the
cellular sources of NO in the condition being
evaluated, and the generation of other reactive
nitrogen species from NO, particularly those
involved in nitrosation and nitration reactions.
When these influences are accounted for one can
predict if nitric oxide will play an anti- or pro-
inflammatory role.
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